Barclays PLC Acquires 3,594 Shares of Celcuity Inc. (NASDAQ:CELC)

Barclays PLC increased its holdings in Celcuity Inc. (NASDAQ:CELC) by 6.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 57,199 shares of the company’s stock after purchasing an additional 3,594 shares during the period. Barclays PLC owned approximately 0.15% of Celcuity worth $749,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Summit Investment Advisors Inc. boosted its stake in shares of Celcuity by 49.5% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,421 shares of the company’s stock worth $45,000 after acquiring an additional 1,132 shares in the last quarter. Bleakley Financial Group LLC acquired a new position in Celcuity during the fourth quarter valued at approximately $146,000. Trexquant Investment LP acquired a new stake in shares of Celcuity in the fourth quarter worth $152,000. SG Americas Securities LLC boosted its holdings in shares of Celcuity by 83.2% during the 4th quarter. SG Americas Securities LLC now owns 14,646 shares of the company’s stock worth $192,000 after buying an additional 6,651 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in Celcuity by 22.3% in the 4th quarter. JPMorgan Chase & Co. now owns 14,683 shares of the company’s stock valued at $192,000 after buying an additional 2,676 shares during the last quarter. 63.33% of the stock is owned by institutional investors and hedge funds.

Celcuity Stock Down 6.7 %

Shares of CELC opened at $10.12 on Wednesday. The company has a 50-day moving average price of $10.06 and a two-hundred day moving average price of $11.96. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65. The stock has a market cap of $382.93 million, a price-to-earnings ratio of -3.88 and a beta of 0.56. Celcuity Inc. has a 12 month low of $7.58 and a 12 month high of $19.77.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings data on Monday, March 31st. The company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.13). Equities analysts predict that Celcuity Inc. will post -2.62 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. HC Wainwright restated a “buy” rating and set a $27.00 price target on shares of Celcuity in a report on Tuesday, April 1st. Needham & Company LLC reaffirmed a “buy” rating and issued a $29.00 target price on shares of Celcuity in a report on Friday, April 11th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Celcuity currently has a consensus rating of “Buy” and a consensus price target of $30.17.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.